8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Jan 8, 2026·SEC
KalVista Pharmaceuticals, Inc.(KALV)Earnings, Financials & Key Ratios
KALV•NASDAQ
$26.71
$1.37B mkt cap·Price updated May 6, 2026
AboutKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$187M-34.0%
- Net Income-$183M-44.9%
- EPS (Diluted)-3.69-7.3%
- ROE-121.5%-76.3%
- ROIC-152.29%-113.4%
- Debt/Equity0.07+86.7%
- Interest Coverage-30.12
KALV Key Insights
KalVista Pharmaceuticals, Inc. (KALV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 95 (top 5%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 44.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 35.0% in last year
- ✗Expensive at 13.9x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KALV Price & Volume
KalVista Pharmaceuticals, Inc. (KALV) stock price & volume — 10-year historical chart
Loading chart...
KALV Growth Metrics
KalVista Pharmaceuticals, Inc. (KALV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.16%
Return on Capital
10 Years-67.07%
5 Years-60.22%
3 Years-75.06%
Last Year-89.91%
KALV Recent Earnings
KalVista Pharmaceuticals, Inc. (KALV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 5, 2026EPS
$0.92
Est $0.38
-144.5%
Revenue
$14M
Est $39M
-65.0%
Q2 2026
Mar 24, 2026EPS
$1.01
Est $0.54
-87.0%
Revenue
$1M
Est $5M
-73.4%
Q4 2025
Nov 10, 2025EPS
$0.92
Est $0.96
+4.2%
Revenue
$14M
Est $32M
-57.6%
Q4 2025
Sep 11, 2025EPS
$1.12
Est $0.91
-23.1%
Revenue
$1M
Est $13M
-88.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.92vs $0.38-144.5% | $14Mvs $39M-65.0% |
| Q2 2026 | Mar 24, 2026 | $1.01vs $0.54-87.0% | $1Mvs $5M-73.4% |
| Q4 2025 | Nov 10, 2025 | $0.92vs $0.96+4.2% | $14Mvs $32M-57.6% |
| Q4 2025 | Sep 11, 2025 | $1.12vs $0.91-23.1% | $1Mvs $13M-88.7% |
Based on last 12 quarters of dataView full earnings history →
KALV Peer Comparison
KalVista Pharmaceuticals, Inc. (KALV) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BDTX | 163.43M | 2.87 | 7.36 | 30.71% | 17.78% | 18.12% | 0.13 | |
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 KALA | 833.23K | 0.11 | -0.02 | -141.11% | -388.29% | 2.62 | ||
 XOMA | 494.04M | 41.66 | 28.53 | 83.06% | 56.4% | 31.88% | 0.58% | 1.57 |
 AGEN | 147.29M | 4.17 | -1226.47 | 10.37% | 0.1% | |||
 ADMA | 2.44B | 10.25 | 12.65 | 65.15% | 42.87% | 48.57% | 4.51% | 0.24 |
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 ARDX | 1.75B | 7.13 | -27.42 | 22.09% | -13.58% | -38.11% | 1.27 |
Compare KALV vs Peers
KalVista Pharmaceuticals, Inc. (KALV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KALV Income Statement
KalVista Pharmaceuticals, Inc. (KALV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.5M | 8.39M | 16.13M | 12.69M | 0 | 0 | 0 | 0 | 0 | 15.12M |
| Revenue Growth % | -29.49% | 458.11% | 92.13% | -21.31% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 12.67K | 18.24K | 35.02K | 40.19M | 41.29M | 0 | 0 | 86.17M | 0 | 17.71M |
| COGS % of Revenue | 0.84% | 0.22% | 0.22% | 316.74% | - | - | - | - | - | - |
| Gross Profit | 1.49M▲ 0% | 8.38M▲ 461.6% | 16.09M▲ 92.1% | -27.5M▼ 270.9% | -41.29M▼ 50.1% | 0▲ 100.0% | 0▲ 0% | -86.17M▲ 0% | 0▲ 100.0% | -2.6M▲ 0% |
| Gross Margin % | 99.16% | 99.78% | 99.78% | -216.74% | - | - | - | - | - | -17.16% |
| Gross Profit Growth % | -29.6% | 461.63% | 92.13% | -270.92% | -50.11% | 100% | - | - | 100% | - |
| Operating Expenses | 23.84M | 27.1M | 45.95M | 13.03M | 16.64M | 96.61M | 110.87M | 54.28M | 188M | 200.43M |
| OpEx % of Revenue | 1585.31% | 322.84% | 284.91% | 102.67% | - | - | - | - | - | - |
| Selling, General & Admin | 11.18M | 8.86M | 10.93M | 13.03M | 16.64M | 26.45M | 30.59M | 54.28M | 116.29M | 160.69M |
| SG&A % of Revenue | 743.15% | 105.58% | 67.75% | 102.67% | - | - | - | - | - | - |
| Research & Development | 12.67M | 18.24M | 35.02M | 40.19M | 41.29M | 70.17M | 80.28M | 86.17M | 71.71M | 55.64M |
| R&D % of Revenue | 842.15% | 217.26% | 217.16% | 316.74% | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -40.19M | -41.29M | 0 | 0 | -86.17M | 0 | -1000K |
| Operating Income | -22.34M▲ 0% | -18.7M▲ 16.3% | -29.82M▼ 59.4% | -40.53M▼ 35.9% | -57.92M▼ 42.9% | -96.61M▼ 66.8% | -110.87M▼ 14.8% | -140.44M▼ 26.7% | -188M▼ 33.9% | -203.03M▲ 0% |
| Operating Margin % | -1485.31% | -222.84% | -184.91% | -319.41% | - | - | - | - | - | -1342.96% |
| Operating Income Growth % | -47.15% | 16.27% | -59.42% | -35.93% | -42.9% | -66.8% | -14.76% | -26.67% | -33.86% | - |
| EBITDA | -22.3M | -18.52M | -29.44M | -40.02M | -57.39M | -96.05M | -110.15M | -139.63M | -187.05M | -201.92M |
| EBITDA Margin % | -1482.65% | -220.69% | -182.56% | -315.37% | - | - | - | - | - | -1335.61% |
| EBITDA Growth % | -48.19% | 16.92% | -58.93% | -35.93% | -43.39% | -67.37% | -14.68% | -26.76% | -33.97% | -18.25% |
| D&A (Non-Cash Add-back) | 40K | 180K | 378K | 512K | 537K | 564K | 718K | 816K | 941K | 1.11M |
| EBIT | -22.34M | -18.7M | -29.82M | -40.53M | -57.92M | -81.31M | -95.09M | -135.1M | -174.27M | -193.44M |
| Net Interest Income | 36K | 82K | 1.4M | 1.83M | 903K | 1.09M | 2.23M | 0 | 650K | -6.95M |
| Interest Income | 36K | 82K | 1.4M | 1.83M | 903K | 1.09M | 2.23M | 0 | 6.43M | 7.11M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.79M | 14.06M |
| Other Income/Expense | 3.74M | 2.9M | 9.13M | 11.54M | 11.68M | 14.27M | 17.96M | 5.35M | 7.94M | 422K |
| Pretax Income | -18.6M▲ 0% | -15.8M▲ 15.0% | -20.69M▼ 30.9% | -28.99M▼ 40.1% | -46.24M▼ 59.5% | -82.34M▼ 78.1% | -92.91M▼ 12.8% | -135.1M▼ 45.4% | -180.05M▼ 33.3% | -202.61M▲ 0% |
| Pretax Margin % | -1236.9% | -188.29% | -128.31% | -228.46% | - | - | - | - | - | -1340.17% |
| Income Tax | 0 | 0 | 124K | 124K | 0 | 0 | 0 | -8.45M | 3.39M | 7.71M |
| Effective Tax Rate % | 0% | 0% | -0.6% | -0.43% | 0% | 0% | 0% | 6.26% | -1.88% | -3.8% |
| Net Income | -18.6M▲ 0% | -15.8M▲ 15.0% | -20.82M▼ 31.7% | -29.12M▼ 39.9% | -46.24M▼ 58.8% | -82.34M▼ 78.1% | -92.91M▼ 12.8% | -126.64M▼ 36.3% | -183.44M▼ 44.9% | -210.31M▲ 0% |
| Net Margin % | -1236.9% | -188.29% | -129.08% | -229.44% | - | - | - | - | - | -1391.14% |
| Net Income Growth % | -62.67% | 15.04% | -31.71% | -39.87% | -58.83% | -78.05% | -12.83% | -36.31% | -44.85% | -34.48% |
| Net Income (Continuing) | -18.6M | -15.8M | -20.82M | -29.12M | -46.24M | -82.34M | -92.91M | -126.64M | -183.44M | -210.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.92▲ 0% | -1.53▲ 20.3% | -1.38▲ 9.8% | -1.64▼ 18.8% | -2.33▼ 42.1% | -3.36▼ 44.2% | -3.33▲ 0.9% | -3.44▼ 3.3% | -3.69▼ 7.3% | -3.90▲ 0% |
| EPS Growth % | 20% | 20.31% | 9.8% | -18.84% | -42.07% | -44.21% | 0.89% | -3.3% | -7.27% | -10.16% |
| EPS (Basic) | -1.92 | -1.53 | -1.38 | -1.64 | -2.33 | -3.36 | -3.33 | -3.44 | -3.69 | - |
| Diluted Shares Outstanding | 9.71M | 10.32M | 15.08M | 17.75M | 19.09M | 24.47M | 27.89M | 36.79M | 49.65M | 53.88M |
| Basic Shares Outstanding | 9.71M | 10.32M | 15.08M | 17.75M | 19.09M | 24.47M | 27.89M | 36.79M | 49.65M | 53.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KALV Balance Sheet
KalVista Pharmaceuticals, Inc. (KALV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 34.25M | 59.38M | 115.55M | 88.7M | 264.26M | 193.65M | 172.33M | 225.69M | 241.69M | 325.23M |
| Cash & Short-Term Investments | 30.95M | 51.05M | 100.81M | 67.71M | 248.93M | 166.2M | 149.38M | 210.4M | 187.65M | 309.16M |
| Cash Only | 30.95M | 51.05M | 32.01M | 15.79M | 50.59M | 30.73M | 56.24M | 31.79M | 98.64M | 243.5M |
| Short-Term Investments | 0 | 0 | 68.81M | 51.92M | 198.34M | 135.47M | 93.14M | 178.61M | 89M | 65.66M |
| Accounts Receivable | 2.55M | 6.83M | 11.31M | 16.53M | 11.72M | 16.81M | 18.64M | 10.87M | 15.14M | 7.12M |
| Days Sales Outstanding | 618.12 | 297.17 | 256.09 | 475.36 | - | - | - | - | - | 230.35 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 458K |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 2.36 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.21M | 8.49M |
| Total Non-Current Assets | 97K | 2.01M | 2.59M | 3.83M | 7.75M | 10.23M | 10.88M | 9.71M | 9.08M | 14.71M |
| Property, Plant & Equipment | 97K | 1.84M | 2.41M | 3.65M | 7.55M | 10.04M | 10.77M | 9.15M | 1.99M | 12.29M |
| Fixed Asset Turnover | 15.51x | 4.57x | 6.68x | 3.47x | - | - | - | - | - | 2.10x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 173K | 173K | 178K | 200K | 193K | 106K | 567K | 7.09M | 13.28M |
| Total Assets | 34.34M▲ 0% | 61.39M▲ 78.7% | 118.13M▲ 92.4% | 92.53M▼ 21.7% | 272.01M▲ 194.0% | 203.88M▼ 25.0% | 183.2M▼ 10.1% | 235.4M▲ 28.5% | 250.77M▲ 6.5% | 339.93M▲ 0% |
| Asset Turnover | 0.04x | 0.14x | 0.14x | 0.14x | - | - | - | - | - | 0.06x |
| Asset Growth % | 38.8% | 78.74% | 92.43% | -21.67% | 193.98% | -25.05% | -10.14% | 28.49% | 6.53% | 267.7% |
| Total Current Liabilities | 3.02M | 23.22M | 18.05M | 7.72M | 9.77M | 11.58M | 15.03M | 22.81M | 45.17M | 45.07M |
| Accounts Payable | 1.15M | 1.43M | 2.86M | 1.68M | 1.98M | 3.64M | 4.82M | 9.11M | 4.88M | 8.07M |
| Days Payables Outstanding | 33.23K | 28.68K | 29.81K | 15.23 | 17.51 | - | - | 38.58 | - | 127.15 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 18.48M | 9.54M | 0 | 0 | 0 | 0 | 0 | 11M | 33.92M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 3.51M | 4.17M | 4.21M | 6.69M | 0 | 14.28M |
| Current Ratio | 11.35x | 2.56x | 6.40x | 11.49x | 27.04x | 16.73x | 11.46x | 9.90x | 5.35x | 5.35x |
| Quick Ratio | 11.35x | 2.56x | 6.40x | 11.49x | 27.04x | 16.73x | 11.46x | 9.90x | 5.35x | 5.35x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 105.55 |
| Total Non-Current Liabilities | 1.15M | 10.92M | 3.34M | 1.06M | 5.05M | 7.21M | 7.14M | 6.01M | 110.21M | 277.86M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 139.03M |
| Capital Lease Obligations | 0 | 58K | 0 | 1.06M | 5.05M | 7.21M | 7.14M | 6.01M | 4.33M | 21.82M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 10.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 362.94M |
| Total Liabilities | 3.02M | 34.14M | 21.39M | 8.78M | 14.82M | 18.79M | 22.18M | 28.82M | 155.38M | 322.93M |
| Total Debt | 0 | 279K | 54K | 1.65M | 5.91M | 8.19M | 8.23M | 7.32M | 6.31M | 149.59M |
| Net Debt | -30.95M | -50.78M | -31.95M | -14.14M | -44.68M | -22.54M | -48.01M | -24.47M | -92.34M | -93.91M |
| Debt / Equity | - | 0.01x | 0.00x | 0.02x | 0.02x | 0.04x | 0.05x | 0.04x | 0.07x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.74x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.47x |
| Interest Coverage | - | - | - | - | - | - | - | - | -30.12x | -13.75x |
| Total Equity | 31.33M▲ 0% | 27.25M▼ 13.0% | 96.74M▲ 255.0% | 83.75M▼ 13.4% | 257.19M▲ 207.1% | 185.09M▼ 28.0% | 161.03M▼ 13.0% | 206.58M▲ 28.3% | 95.39M▼ 53.8% | 17M▲ 0% |
| Equity Growth % | 45.73% | -13% | 254.96% | -13.42% | 207.09% | -28.03% | -13% | 28.29% | -53.82% | -153.7% |
| Book Value per Share | 3.23 | 2.64 | 6.41 | 4.72 | 13.47 | 7.56 | 5.77 | 5.62 | 1.92 | 0.32 |
| Total Shareholders' Equity | 31.33M | 27.25M | 96.74M | 83.75M | 257.19M | 185.09M | 161.03M | 206.58M | 95.39M | 17M |
| Common Stock | 10K | 11K | 17K | 18K | 24K | 25K | 34K | 42K | 50K | 50K |
| Retained Earnings | -55.85M | -71.66M | -92.48M | -121.59M | -167.84M | -250.18M | -343.08M | -469.73M | -653.17M | -739.1M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.64M | -1.11M | -1.93M | -1.88M | -1.43M | -3.86M | -3.06M | -3.49M | -5.21M | -6.73M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KALV Cash Flow Statement
KalVista Pharmaceuticals, Inc. (KALV) cash flow — operating, investing & free cash flow history
| Line item | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -23.72M | 10.56M | -36.37M | -44.82M | -30.17M | -78.13M | -75.26M | -89.23M | -152.91M | -152.91M |
| Operating CF Margin % | -1577.26% | 125.78% | -225.49% | -353.16% | - | - | - | - | - | - |
| Operating CF Growth % | -80.31% | 144.51% | -444.43% | -23.24% | 32.68% | -158.97% | 3.68% | -18.56% | -71.36% | -203.71% |
| Net Income | -18.6M | -15.8M | -20.82M | -29.12M | -46.24M | -82.34M | -92.91M | -126.64M | -183.44M | -210.31M |
| Depreciation & Amortization | 40K | 180K | 378K | 512K | 537K | 743K | 718K | 816K | 941K | 985K |
| Stock-Based Compensation | 394K | 1.06M | 2.97M | 4.45M | 7.12M | 0 | 9.92M | 21.91M | 12.29M | 5.53M |
| Deferred Taxes | 0 | 0 | 0 | -33K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.37M | -651K | -103K | 13K | 72K | 15.78M | -407K | -485K | 2.27M | 42.67M |
| Working Capital Changes | -4.18M | 25.77M | -18.79M | -20.64M | 8.35M | -12.32M | 7.41M | 15.17M | 15.04M | 894K |
| Change in Receivables | -571K | -3.94M | -4.88M | -5.78M | 7.46M | -5.2M | -2.32M | 8.18M | -3.62M | -1.79M |
| Change in Inventory | 0 | 0 | 4.88M | 5.78M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.6M | 217K | 1.53M | -1M | 150K | 1.69M | 1.11M | 4.32M | -4.97M | 6.87M |
| Cash from Investing | 34.06M | -1.43M | -69.42M | 16.75M | -147.65M | 57.86M | 41.41M | -84.72M | 91.02M | 34.97M |
| Capital Expenditures | -74K | -1.43M | -1.08M | -220K | -82K | -931K | -1.2M | -42K | -929K | -314K |
| CapEx % of Revenue | 4.92% | 17% | 6.7% | 1.73% | - | - | - | - | - | - |
| Acquisitions | 34.14M | 0 | 69.42M | -16.75M | 0 | 0 | 0 | 0 | 0 | 434K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 34.14M | -1.43M | -69.42M | 16.75M | 0 | 0 | 0 | -401K | 0 | -54.79M |
| Cash from Financing | 2K | 8.99M | 87.94M | 11.58M | 212.12M | 1.58M | 58.12M | 150.71M | 159.73M | 331.42M |
| Debt Issued (Net) | 0 | -151K | -209K | -54K | 0 | 0 | 0 | 0 | 98.04M | 24.73M |
| Equity Issued (Net) | 0 | 9.14M | 87.91M | 11.42M | 210.58M | 1.58M | 56.58M | 96.94M | 61.69M | 3.14M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2K | 0 | 242K | 216K | 1.53M | 0 | 1.53M | 53.77M | 0 | 303.55M |
| Net Change in Cash | 9.19M▲ 0% | 20.11M▲ 118.9% | -19.05M▼ 194.7% | -16.22M▲ 14.9% | 34.8M▲ 314.6% | -19.86M▼ 157.1% | 25.51M▲ 228.4% | -24.45M▼ 195.9% | 99.83M▲ 508.3% | 209.74M▲ 0% |
| Free Cash Flow | -23.8M▲ 0% | 9.13M▲ 138.4% | -37.45M▼ 510.1% | -45.04M▼ 20.3% | -30.25M▲ 32.8% | -79.06M▼ 161.3% | -76.46M▲ 3.3% | -89.67M▼ 17.3% | -153.34M▼ 71.0% | -160.32M▲ 0% |
| FCF Margin % | -1582.18% | 108.78% | -232.19% | -354.89% | - | - | - | - | - | -1060.45% |
| FCF Growth % | -80.72% | 138.37% | -510.1% | -20.27% | 32.82% | -161.35% | 3.3% | -17.29% | -71% | -30.54% |
| FCF per Share | -2.45 | 0.88 | -2.48 | -2.54 | -1.58 | -3.23 | -2.74 | -2.44 | -3.09 | -3.09 |
| FCF Conversion (FCF/Net Income) | 1.28x | -0.67x | 1.75x | 1.54x | 0.65x | 0.95x | 0.81x | 0.70x | 0.83x | 0.76x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KALV Key Ratios
KalVista Pharmaceuticals, Inc. (KALV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -70.44% | -53.96% | -33.58% | -32.26% | -27.13% | -37.23% | -53.69% | -68.9% | -121.5% | -282.01% |
| Return on Invested Capital (ROIC) | -710.23% | - | -108.4% | -45.24% | -30.8% | -38.64% | -60.35% | -71.38% | -152.29% | -152.29% |
| Gross Margin | 99.16% | 99.78% | 99.78% | -216.74% | - | - | - | - | - | -17.16% |
| Net Margin | -1236.9% | -188.29% | -129.08% | -229.44% | - | - | - | - | - | -1391.14% |
| Debt / Equity | - | 0.01x | 0.00x | 0.02x | 0.02x | 0.04x | 0.05x | 0.04x | 0.07x | 0.07x |
| Interest Coverage | - | - | - | - | - | - | - | - | -30.12x | -13.75x |
| FCF Conversion | 1.28x | -0.67x | 1.75x | 1.54x | 0.65x | 0.95x | 0.81x | 0.70x | 0.83x | 0.76x |
| Revenue Growth | -29.49% | 458.11% | 92.13% | -21.31% | -100% | - | - | - | - | - |
KALV SEC Filings & Documents
KalVista Pharmaceuticals, Inc. (KALV) SEC filings — annual & quarterly reports (10-K, 10-Q)
KALV Frequently Asked Questions
KalVista Pharmaceuticals, Inc. (KALV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
KalVista Pharmaceuticals, Inc. (KALV) reported $15.1M in revenue for fiscal year 2025. This represents a 883% increase from $1.5M in 2013.
KalVista Pharmaceuticals, Inc. (KALV) grew revenue by 0.0% over the past year. Growth has been modest.
KalVista Pharmaceuticals, Inc. (KALV) reported a net loss of $210.3M for fiscal year 2025.
Dividend & Returns
KalVista Pharmaceuticals, Inc. (KALV) has a return on equity (ROE) of -121.5%. Negative ROE indicates the company is unprofitable.
KalVista Pharmaceuticals, Inc. (KALV) had negative free cash flow of $160.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More KALV
KalVista Pharmaceuticals, Inc. (KALV) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates